anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: To reduce the overuse of magnetic resonance cholangiopancreatography and the rates of non-therapeutic endoscopic retrograde cholangiopancreatography in pediatric patients suspected of choledocholithiasis.
MATERIALS AND METHODS: Retrospective study of patients suspected of choledocholithiasis between January 2010 and June 2023. Patients with cholangitis or two or more of the following predictive factors of choledocholithiasis in initial laboratory tests and ultrasound were categorized as high-risk group: total bilirubin level ≥ 2 mg/dl, common bile duct > 6 millimeters on ultrasound; and detection of choledocholithiasis by ultrasound. Patients were recategorized according to the results of the second set of laboratory and ultrasound analysis. Confirmatory modalities (magnetic resonance cholangiopancreatography, endoscopic retrograde cholangiopancreatography, and/or intraoperative cholangiography) were used to evaluate the presence of choledocholithiasis. Finally, we assessed the predictive capability of both the initial high-risk group and the group after recategorization.
RESULTS: A total of 129 patients were included. After initial studies, 72 (55.8%) patients were classified into the high-risk group. After recategorization, only 29 (22.5%) patients were included in this group. The sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of the initial high-risk group were 89.3%, 53.5%, 34.7%, 94.7%, and 61.2%, respectively, while after recategorization, they were 82.1%, 94.1%, 79.3%, 95.0%, and 91.5%, respectively.
CONCLUSIONS: Recategorization of the risk of choledocholithiasis would significantly improve the diagnostic accuracy of choledocholithiasis and help reduce the overuse of more complex and unnecessary studies/procedures.
BACKGROUND: Cardiogenic shock remains highly associated with early mortality, with mortality often exceeding 50%. We sought to determine the association between prognostic factors and in-hospital and 30-day mortality in cardiogenic shock.
METHODS: We performed a systematic review and meta-analysis of prognostic factors in cardiogenic shock, searching MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for records up to June 5, 2023. English-language studies that investigated prognostic factors and in-hospital and/or 30-day mortality in cardiogenic shock were included. Studies were excluded if they evaluated the pediatric population, were postmortem studies, or included fewer than 100 patients. The primary aim was to identify modifiable and non-modifiable prognostic factors associated with in-hospital and 30-day mortality in cardiogenic shock.
RESULTS: We identified 160 studies, including 2,459,703 patients with a median in-hospital mortality of 41.4% (interquartile range, 33.6% to 49.2%). The majority were retrospective cohort studies. Patient factors potentially associated with an increase in early mortality included an age greater than or equal to 75 years of age, peripheral arterial disease, chronic kidney disease, and female sex. Procedural and presentation factors potentially associated with increased mortality included out-of-hospital cardiac arrest, left main culprit artery, left ventricular ejection fraction less than 30%, dialysis, and need for mechanical circulatory support. Revascularization in the form of coronary artery bypass graft and percutaneous coronary intervention were potentially associated with reduced in-hospital mortality.
CONCLUSIONS: This analysis quantifies the association between patient, presentation, and treatment-related factors and early mortality in cardiogenic shock. Increased certainty in the association of these prognostic factors with cardiogenic shock outcomes can aid in clinical risk assessment, development of risk tools, and analysis of clinical trials.
1,199,887. Lyophilized aloe gel. J. R. MARSH. 29 April, 1969, No. 21779/69. Heading A5B. Lyophilized aloe gel in the form of dry anhydrous crystals is prepared by removing the gel from the leaves of an aloe plant, preferably the aloe vera plant, macerating the gel in a container, screening or filtering the macerated gel, placing the screened or filtered gel in containers within a freezing machine, freezing the gel to from 0C to -120C. and administering a vacuum to the frozen gel in the containers until anhydrous crystals of the gel remain in the containers. Reconstituted aloe gel, having the same physical and chemical properties as aloe gel prior to lyophilization, is prepared by adding water, preferably deionized or distilled water, to the anhydrous crystals prepared as above. The anhydrous crystals may be placed in sealed containers for storage or shipment prior to their use in pharmaceutical preparations, cosmetics and/or toiletries.
<P>PROBLEM TO BE SOLVED: To provide a bath agent composition which comprises a uniform dispersion of orange oil in an aqueous medium, enables efficient bathing by quickly and uniformly dispersing in hot water to which it is added, brings mental stability to a bathing baby with its soft orange fragrance, is excellent in temporal stability in spite of being an aqueous emulsion, causes no separation of components after long-term storage, is excellent in moisturizing effect derived from ceramide contained as an ingredient, is slightly acidic and is therefore gentle to the skin and suitable for bathing babies with sensitive skin.  <P>SOLUTION: In the bath agent composition, the orange oil is uniformly dispersed in the aqueous medium. The bath agent composition contains 30-980 pts.wt. water against 1 pt.wt. orange oil.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Individuals diagnosed with Chronic Obstructive Pulmonary Disease (COPD) are exposed to an increased risk of metabolic syndrome (MetS), which negatively affects their health outcomes and quality of life. Lifestyle interventions have shown promise in managing MetS. This study outlines the protocol for a web-based multimodal self-care program, Digital Metabolic Rehabilitation, for managing MetS in patients with COPD. The Digital Metabolic Rehabilitation is a single-arm pilot trial that integrates the Canadian Health Advanced by Nutrition and Graded Exercise (CHANGE) Program and a web-based wellness platform. The web-based wellness platform employed in this study is My Viva Plan (MVP)®, which integrates a holistic, multicomponent approach to promote wellness. The intervention will primarily focus on lifestyle changes for patients with COPD. Over 6 months, participants will use the web-based wellness platform and engage in weekly online support group sessions. Fifty patients diagnosed with stage I-II COPD and MetS will participate. Blood tests, anthropometrics, body composition, physical function, muscle strength, physical activity, energy metabolism, quality of life and mental health will be assessed at baseline, 3, and 6 months. The Digital Metabolic Rehabilitation program aims to explore whether a multimodal integrative intervention delivered through a web-based wellness platform can be implemented by patients with COPD with MetS. By combining the expertise of the CHANGE Program with the digital delivery format, the intervention seeks to enhance self-monitoring and foster better self-management practices. The protocol outlines a novel and potentially impactful intervention for managing MetS in patients with COPD.
Nafcillin for Injection is available for intramuscular and intravenous use. 

The usual IV dosage for adults is 500 mg every 4 hours. For severe infections, 1 gram every 4 hours is recommended. Administer slowly over at least 30 to 60 minutes to minimize the risk of vein irritation and extravasation. 

Bacteriologic studies to determine the causative organisms and their susceptibility to nafcillin should always be performed. Duration of therapy varies with the type and severity of infection as well as the overall condition of the patient; therefore, it should be determined by the clinical and bacteriological response of the patient. In severe staphylococcal infections, therapy with nafcillin should be continued for at least 14 days. The treatment of endocarditis and osteomyelitis may require a longer duration of therapy. 

No dosage alterations are necessary for patients with renal dysfunction, including those on hemodialysis. Hemodialysis does not accelerate nafcillin clearance from the blood. 

With intravenous administration, particularly in elderly patients, care should be taken because of the possibility of thrombophlebitis. 

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. 

Do not add supplementary medication to Nafcillin.
The recent statistics showed that mental disorders affect one in four people in the world. In this context, informal caregivers are key actors in the health care system through their support. This support can be associated with very high burden and distress. Informal caregivers can experience serious situations with potential negative consequences on their quality of life, their own health and the health of patients. Data recommended to intervene at the onset of disease to improve the impact of an intervention. It seems important also to intervene while the patient is in an acute phase of illness to better support informal caregivers' emotional needs. In addition, providing emotional support for informal caregivers at the beginning of an illness in particular is recommended because this is a critical phase. The experience of painful emotions, such as denial of disease and feelings of being overwhelmed or shocked can have serious consequences on their health and on the patient's recovery. Previous studies identified that informal caregivers need tailored knowledge about the patient's illness, clarification about their roles and responsibilities, better control over their own life and effective collaboration with health professionals. Most of the interventions published in the literature focus on the ill family member and its support but not on the specific needs of the informal caregivers as the core intervention. To reduce the gap between scientific recommendations and actual practice, the investigators developed, tailored and tested a new intervention called Ensemble.

Ensemble is a brief individualized intervention designed to promote the well-being of informal caregivers who experience the effects of patients' psychiatric disorders. The five-session Ensemble program provided to informal caregivers targeted support to address their specific unmet needs, emotions and social resources. A professional addressed this programme to the informal caregiver delivered independently of the patient's treatment.

Ensemble assesses the needs of informal caregivers and provides a tailored brief support. Results of a pilot study showed that psychological health and optimism of informal caregivers were improved. For these reasons, there is a clear research and clinical need to establish whether Ensemble programme is clinically effective by using a randomized, controlled, and assessor-blind trial. A combination of Ensemble plus support as usual (SAU) will be compared to SAU alone. Informal caregivers of individuals suffering from mental disorders will undergo either intervention for five sessions, during a six weeks average time. Measure will assess participants' current psychological health state and optimism. These different measures will be performed at the time of inclusion, at the end of the intervention, and at two months follow-up. At the end of the program, individual qualitative structured interviews will be performed to assess acceptability of the programme.
Substantially purified salivary  Lu. longipalpis  polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the  Lu. longipalpis  polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing  Leishmaniasis  are disclosed.
Participants who received two doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and no additional doses of the HZ/su vaccine in the ZOSTER-049 study, but who served as a control for the two groups that received 1 or 2 additional doses of HZ/su (1-Additional Dose and Revaccination groups). In the current ZOSTER-101 study, this Control group is used in the evaluation of the long-term vaccine efficacy, safety and as a control for persistence of immunogenicity to additional doses administered in ZOSTER-049 study.
The invention discloses a Chinese medicinal composition for treating enterophthisis with a syndrome of stagnation of the liver-Qi attacking spleen. When a person is damaged by excess of seven emotions and has an emotional stress, the person is in disorder of qi movement and has liver failure, the spleen is invaded unreasonably, and the healthy transportation is lost, so that the person suffers from abdominal pains and diarrhea. Liver dysfunction results in chest distress and rib-side distention. Belching with reduced appetite, a pink tongue and stringy pulse shows a phenomenon of liver-yang hyperactivity and spleen deficiency. The Chinese medicinal composition is prepared from traditional Chinese medicinal materials including herb of stickyhair pearleverlasting, caraway, dutchmanspipe root, nard, clerodendron bungei root, wild sorghum, orange peel, roots of uraria crinit, clove tree back and red garden burnet. The Chinese medicinal composition is prepared into a decoction in a drug manufacturing room of our hospital, and clinical tests show that the total effective rate of the composition is 97.5% and the curative effect is very significant.
Non-alcoholic fatty liver disease is associated with an irregular serine metabolism. Serine hydroxymethyltransferase 2 (SHMT2) is a liver enzyme that breaks down serine into glycine and one-carbon (1C) units critical for liver methylation reactions and overall health. However, the contribution of SHMT2 to hepatic 1C homeostasis and biological functions has yet to be defined in genetically modified animal models. We created a mouse strain with targeted SHMT2 knockout in hepatocytes to investigate this. The absence of SHMT2 increased serine and glycine levels in circulation, decreased liver methylation potential, and increased susceptibility to fatty liver disease. Interestingly, SHMT2-deficient mice developed simultaneous fatty liver, but when fed a diet high in fat, fructose, and cholesterol, they had significantly less inflammation and fibrosis. This study highlights the critical role of SHMT2 in maintaining hepatic 1C homeostasis and its stage-specific functions in the pathogenesis of NAFLD.
Study #1 is made up of three sessions done on three separate days and the entire study can be completed in as little as two weeks. All testing sessions will take place at the Exercise Physiology Research Laboratory. Volunteers will be asked to participate in one initial testing session (Visit 1) lasting \< 1 hour that will help make them more familiar with the study equipment and procedures, determine body measures (height, weight, body fat), determine the maximum strength of their forearm and calf, and require one blood draw. The following two testing sessions (Visits 2 and 3) with each session lasting between 2-3 hours that will involve multiple tests designed to determine the health of their blood vessels. For Visit #2 they will be randomly given either antioxidant pills or placebo pills to determine the effect of oxidants on blood vessel health. For Visit #3, they will be given whatever set of pills (antioxidant or placebo) that they did not receive during Visit #2.
Inflammatory bowel diseases (IBD) are characterized by chronic and relapsing inflammation affecting the gastrointestinal (GI) tract. The incidence and prevalence of IBD are relatively high and still increasing. Additionally, current therapeutic strategies for IBD are not optimal. These facts urge todays' medicine to find a novel way to treat IBD. Here, we focused on the group of anti-diabetic drugs called gliflozins, which inhibit sodium glucose co-transporter type 2 (SGLT-2). Numerous studies demonstrated that gliflozins exhibit pleiotropic effect, including anti-inflammatory properties. In this study, we tested the effect of three gliflozins; empagliflozin (EMPA), dapagliflozin (DAPA), and canagliflozin (CANA) in in vitro and in vivo models of intestinal inflammation. Our in vitro experiments revealed that EMPA and DAPA suppress the production of nitric oxide in LPS-treated murine RAW264.7 macrophages. In in vivo part of our study, we showed that EMPA alleviates acute DSS-induced colitis in mice. Treatment with EMPA reduced macro- and microscopic colonic damage, as well as partially prevented from decrease in tight junction gene expression. Moreover, EMPA attenuated biochemical inflammatory parameters including reduced activity of myeloperoxidase. We showed that SGLT-2 inhibitors act as anti-inflammatory agents independently from their hypoglycemic effects. Our observations suggest that gliflozins alleviate inflammation through their potent effects on innate immune cells.
PROBLEM TO BE SOLVED: To obtain the subject cosmetic excellent in sliding property and having soft, smooth and excellent feeling to users by including spherical powder and plate-like powder. SOLUTION: This cosmetic comprises (A) spherical powder, preferably having 0.05-100 μm average particle diameter (e.g. polymethylsilsesquioxane powder) and (B) plate-like, preferably boron nitride, sericite, mica, etc. In the cosmetic, the component A is preferably contained in an amount of 0.10-10 wt.% and the component B is preferably contained in an amount of 0.1-20 wt.%. Preferably, the weight ratio of the component A to the component B is (0.1:20) to (10:0.1). Persistency of makeup effect of the cosmetic on perspiration and sebum and makeup effect for outstanding eyes when applied to the edge of eyes can be improved.
Patients in this cohort are those diagnosed with vasculitis more than 12 months from study entry and/or were previously enrolled in the ARChiVe or Brainworks registries. Clinical outcome data will be collected retrospectively. Blood (RNA \& serum), urine, and saliva (DNA) will be collected at 2 timepoints: disease flare, and remission/post-flare.
BACKGROUND: This study aimed to investigate the key molecular mechanisms underlying keloid pathogenesis by integrating oxidative stress, mitochondria, and immune cells.
METHODS: Transcriptome sequencing (mRNA, lncRNA, and circRNA expression data), proteomic sequencing, and small RNA sequencing analyses of lesional and non-lesional skin of patients with keloids and healthy control (normal) skin were conducted. By integrating mRNA and publicly available gene expression data (GSE158395), differentially expressed genes related to oxidative stress and mitochondrial function in keloids were identified. Hub genes were identified using various bioinformatics analyses such as immune infiltration analysis, weighted gene co-expression network analysis, machine learning, and expression validation using proteomics sequencing data. Moreover, a competing endogenous RNA (ceRNA) network of hub genes was constructed by combining miRNA, lncRNA, and circRNA expression data. Five hub genes were identified: MGST1, DHCR24, ALDH3A2, ADH1B, and FKBP5.
RESULTS: These hub genes had a high diagnostic value for keloids, with an AUC value > 0.8 each. In addition, five hub genes were associated with the infiltration of multiple immune cells. The immune cells with the strongest positive and negative correlations with hub genes were M0 and M1 macrophages. A ceRNA network was constructed, and several ceRNAs, such as AC005062.1/miR-134-5p/FKBP5 and BASP1-AS1/miR-503-5p/ADH1B, were identified. These five hub genes may contribute to keloid pathogenesis.
CONCLUSION: These genes and their related ceRNAs may serve as diagnostic biomarkers and therapeutic targets for keloids.
The participants will receive the standard counseling that all our patients who are scheduled for urodynamic testing receive (just like those who are assigned to group 1). In addition, the participants will receive intervention: a pre-procedural telephone call from the investigators 1 week before their testing to talk about the procedure.
Study Arm 2) asymptomatic LHON mutation carriers. Can be male or female; have some dysfunction, with changes occurring over months. Patients in study arm 2 will not be exposed to NIR-LED, but only undergo diagnostic studies.
The present invention relates to a drug eluting polymer blend. More particularly, the present invention relates to a medical device with a drug eluting polymer blend incorporated therein wherein the drug elution rate is controlled by cross-linking the polymer blend. Once formed, the polymer blend can be used to create a medical device by itself or in combination with other materials. The drug, or other biologically active agent, can be loaded into the blend by soaking the polymer blend in a solution containing the agent before, during or after formation of the medical device. Alternatively, the drug or agent can be loaded into one of the polymers of the polymer blend before formation of the blend or during formation of the blend. Likewise, the polymer blend can be cross-linked before or after loading the selected drug or biologically active agent. Upon insertion into the body and exposure to the body's fluid, the blend releases the loaded biologically active agent at the desired rate.
The present invention relates to a sensitizing composition using electromagnetic waves for the thermal therapy of cancers, and cancer therapy using same. More particularly, the present invention relates to a sensitizing composition using electromagnetic waves to increase sensitivity for cancer treatment, and cancer therapy using same. The sensitizing composition using electromagnetic waves for the thermal therapy of cancers according to the present invention includes metal ions, a metal ion binding material, "apotransferrin to which metal ions are non-covalently bonded" (transferrin), or an apotransferrin inducer to which metal ions are non-covalently bonded. Since the sensitizing composition for the thermal therapy of cancers according to the present invention has target selectivity for cancers when administered to the human body, metal ions are selectively delivered to cancer tissue. Therefore, heat generation in cancer tissue in which the metal ions are accumulated is increased when thermal therapy of cancers using electromagnetic waves is performed. Thus, it is possible to maximize the cancer treating efficacy of the thermal therapy of cancers using electromagnetic waves. Further, since it is possible to significantly increase cancer treating efficacy without pain and side effects, the present invention is expected to be widely used for anticancer treatment. Also, since it is possible to combine other cancer therapies such as chemotherapy and radiotherapy, the probability of complete recovery from cancer can be increased.